Live Feeds
● TRACKER Updated 12d ago · 7 sources tracked

GSK plans phase 3 after mRNA flu vaccine beats standard shots

GSK is advancing its mRNA influenza vaccine into a Phase III clinical trial utilizing a newer formulation after trial data showed the shot outperformed standard vaccines. The company aims to compete directly against Moderna in the mRNA influenza vaccine market. A Connecticut health official noted that the new shot could provide older adults with better protection against the virus. The upcoming late-stage study follows a successful Phase II trial that demonstrated stronger immune responses and good tolerability for the experimental immunization.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (8)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ GSK is advancing its mRNA flu vaccine into a Phase III clinical trial after a Phase II study demonstrated stronger immune responses and good tolerability.
  • ✓ The upcoming Phase III test will utilize a newer formulation of the vaccine.
  • ✓ The vaccine development positions GSK to compete directly against Moderna in the mRNA flu vaccine space.
🛡️ Source Corroboration: 7 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

GSK officially moved its mRNA influenza vaccine into Phase III development following favorable Phase II results.

Live updates

  1. GSK Advances mRNA Flu Vaccine to Phase 3 Trials

    GSK is advancing its mRNA influenza vaccine into a Phase III clinical trial utilizing a newer formulation after trial data showed the shot outperformed standard vaccines. The company aims to compete directly against Moderna in the mRNA influenza vaccine market. A Connecticut health official noted that the new shot could provide older adults with better protection against the virus. The upcoming late-stage study follows a successful Phase II trial that demonstrated stronger immune responses and good tolerability for the experimental immunization.

    Why it matters

    Traditional influenza vaccines rely on older manufacturing methods that can have variable effectiveness, particularly in older populations. Messenger RNA technology allows for rapid adaptation and potentially more robust immune activation. GSK aims to challenge competitors in the emerging commercial market for mRNA respiratory vaccines.

    What is confirmed

    • GSK is advancing its mRNA flu vaccine into a Phase III clinical trial after a Phase II study demonstrated stronger immune responses and good tolerability.
    • The upcoming Phase III test will utilize a newer formulation of the vaccine.
    • The vaccine development positions GSK to compete directly against Moderna in the mRNA flu vaccine space.

    Still unconfirmed

    • The new shot could give older adults better protection.

    What to watch next

    • Results and timelines from the upcoming Phase III clinical trial.
    • Regulatory updates regarding GSK and competing mRNA influenza programs.
    Sources used for this update (7)
    1. Fierce Biotech — GSK plans phase 3 after mRNA flu vaccine beats standard shots
    2. Yahoo Finance — GSK hopes to take on Moderna as it moves mRNA flu vaccine to Phase III trial
    3. Endpoints News — GSK to launch Phase 3 test of mRNA flu vaccine with newer formulation
    4. Connecticut Public — New flu shot could give older adults better protection, CT health official says
    5. Westlaw Today — GSK to advance mRNA flu vaccine to late-stage trial | Business Information & News | FE
    6. Pharmaceutical Executive — GSK Advances mRNA Flu Vaccine to Phase III
    7. finance.yahoo.com — GSK to Advance mRNA Influenza Vaccine Into Phase III Development
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community